Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

AIMS: Canagliflozin is a sodium glucose co-transporter 2 inhibitor developed for the treatment of type 2 diabetes mellitus (T2DM). This randomised, double-blind, placebo-controlled, Phase 3 study evaluated the efficacy and safety of canagliflozin as an add-on to metformin plus sulphonylurea in patie...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Clin Pract
Main Authors: Wilding, J P H, Charpentier, G, Hollander, P, González-Gálvez, G, Mathieu, C, Vercruysse, F, Usiskin, K, Law, G, Black, S, Canovatchel, W, Meininger, G
Formato: Artigo
Idioma:Inglês
Publicado em: BlackWell Publishing Ltd 2013
Assuntos:
Endocrinology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4282288/
https://ncbi.nlm.nih.gov/pubmed/24118688
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ijcp.12322
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados